Why did Dexcom lower its gross margin guidance if revenue guidance was maintained?

The non-GAAP gross profit margin outlook was reduced to about 62% mainly because of incremental costs tied to near-term supply dynamics, as the company reestablishes optimal finished goods inventory levels. Revenue and operating margin guidance were reiterated, so management is signaling a cost-timing headwind rather than a change in demand.

Is the $750 million share repurchase program a firm commitment to buy back stock?

No. The filing states that Dexcom is not obligated to repurchase any amount or number of shares. Repurchases may be made in the open market, through privately negotiated deals, or under Rule 10b5-1 trading plans, at management's discretion and subject to market conditions. The program runs through June 30, 2026 and can be modified, suspended, or discontinued.

Why did GAAP operating income improve while non-GAAP operating income declined?

GAAP operating income benefited from lower intellectual property litigation costs (about $0.5 million versus $25.2 million a year earlier), which are excluded from non-GAAP results. Non-GAAP operating income fell because the year-ago period had a higher non-GAAP operating margin of 15.2%, and the current quarter's 13.8% reflects higher gross margin pressure.

How strong is Dexcom's balance sheet and liquidity position?

Dexcom held $2.70 billion in cash, cash equivalents and marketable securities at March 31, 2025, and its revolving credit facility was undrawn. However, the balance sheet also carries about $2.44 billion in senior convertible notes, with roughly $1.21 billion classified as current, so near-term refinancing or conversion dynamics are worth monitoring alongside buybacks.

What drove the difference between reported and organic revenue growth?

Organic revenue of $1.046 billion excludes $9.9 million of favorable foreign exchange impact, which is why organic growth (14%) exceeded reported growth (12%). Organic growth also excludes the effect of non-CGM revenue divested over the trailing twelve months, which was $2.8 million in the first quarter of 2024.

DXCM 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed May 1, 2025. Cited figures are marked; the original filing is the authoritative source.

DexCom reported first-quarter 2025 results with revenue of $1.036 billion^a, up 12% year-over-year on a reported basis and 14% on an organic basis, driven by U.S. growth of 15% while international revenue grew 7% reported (12% organic).

GAAP operating income rose to $133.7 million^b (12.9% of revenue, up 190 basis points), while non-GAAP operating income of $143.1 million (13.8% margin) declined 140 basis points year-over-year. GAAP diluted EPS was $0.27 versus $0.36 a year earlier, and non-GAAP diluted EPS was flat at $0.32. Sensor and other revenue grew 17%, while hardware revenue fell 42%.

Management reiterated FY2025 revenue guidance of $4.60 billion^c (14% growth), non-GAAP operating margin of about 21%, and Adjusted EBITDA margin of about 30%, but lowered non-GAAP gross profit margin guidance to roughly 62% due to incremental costs tied to near-term supply dynamics as the company rebuilds finished goods inventory. The company also announced a share repurchase program of up to $750 million, expiring no later than June 30, 2026, with execution at management's discretion and no obligation to buy back any shares. Cash, equivalents and marketable securities totaled $2.70 billion at quarter-end, and the revolving credit facility was undrawn, giving the company meaningful financial flexibility.

For investors, the key tension is between solid top-line momentum and broader payer coverage, including two of the three largest PBMs, against margin pressure from supply-related costs and the year-over-year decline in non-GAAP operating margin. The buyback signals management confidence and balance sheet capacity, though its scale relative to the company's cash position and convertible note obligations warrants monitoring alongside the Dexcom G7 15 Day System launch.

02—Key points

Key Highlights

Revenue grew 12% year-over-year to $1.036 billion reported (14% organic), with U.S. revenue up 15% and international up 7% reported (12% organic).
GAAP operating income of $133.7 million rose 190 basis points to 12.9% of revenue, while non-GAAP operating income of $143.1 million declined 140 basis points to 13.8% margin.
GAAP diluted EPS was $0.27 versus $0.36 a year ago; non-GAAP diluted EPS was $0.32, flat year-over-year.
FY2025 revenue guidance of $4.60 billion (14% growth) and non-GAAP operating margin of about 21% were reiterated, and Adjusted EBITDA margin of about 30% was reaffirmed.
Non-GAAP gross profit margin guidance was lowered to approximately 62% due to incremental costs from supply dynamics as inventory levels are rebuilt.
Board authorized a share repurchase program of up to $750 million, running through June 30, 2026, with no obligation to repurchase.
Ended the quarter with $2.70 billion in cash and marketable securities and an undrawn revolving credit facility; two of the three largest PBMs now cover Dexcom CGM.

03—Questions

Frequently Asked Questions

Why did Dexcom lower its gross margin guidance if revenue guidance was maintained?
The non-GAAP gross profit margin outlook was reduced to about 62% mainly because of incremental costs tied to near-term supply dynamics, as the company reestablishes optimal finished goods inventory levels. Revenue and operating margin guidance were reiterated, so management is signaling a cost-timing headwind rather than a change in demand.
Is the $750 million share repurchase program a firm commitment to buy back stock?
No. The filing states that Dexcom is not obligated to repurchase any amount or number of shares. Repurchases may be made in the open market, through privately negotiated deals, or under Rule 10b5-1 trading plans, at management's discretion and subject to market conditions. The program runs through June 30, 2026 and can be modified, suspended, or discontinued.
Why did GAAP operating income improve while non-GAAP operating income declined?
GAAP operating income benefited from lower intellectual property litigation costs (about $0.5 million versus $25.2 million a year earlier), which are excluded from non-GAAP results. Non-GAAP operating income fell because the year-ago period had a higher non-GAAP operating margin of 15.2%, and the current quarter's 13.8% reflects higher gross margin pressure.
How strong is Dexcom's balance sheet and liquidity position?
Dexcom held $2.70 billion in cash, cash equivalents and marketable securities at March 31, 2025, and its revolving credit facility was undrawn. However, the balance sheet also carries about $2.44 billion in senior convertible notes, with roughly $1.21 billion classified as current, so near-term refinancing or conversion dynamics are worth monitoring alongside buybacks.
What drove the difference between reported and organic revenue growth?
Organic revenue of $1.046 billion excludes $9.9 million of favorable foreign exchange impact, which is why organic growth (14%) exceeded reported growth (12%). Organic growth also excludes the effect of non-CGM revenue divested over the trailing twelve months, which was $2.8 million in the first quarter of 2024.

04—Continue

← View all 8-K filings